Jim Cramer's Top Takeaways: Home Depot, Corbus Pharmaceuticals

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways.

Home Depot (HD)  : Cramer spoke with Carol Tomé, CFO of Home Depot, a 15-year veteran in the home-improvement space and someone Cramer called "the best in the business."

Tomé said that Home Depot has only been selling holiday items since 2006, but this year it will sell over 2.8 million Christmas trees and more than eight million poinsettias -- and expects to have a knockout Black Friday.

Tomé added that the secret to Home Depot's success has always been talking to consumers and giving them what they want. In the past, growth was driven by opening new stores and adding square footage, but today, she said, the company doesn't need new stores and instead focuses on offering new products and services at the stores they already have.

Home Depot continues to invest in the categories that are working the best, such as appliances, and where they are continuing to take share from rivals, Tomé said.

Cramer asked what keeps Tomé going after decades in the business.

She said that doing what she loves has been key to her success. Adding to that success has been working with an amazing team and speaking with experts in the business, all to help formulate an informed point of view on where the industry is headed.

Tomé said that when home prices are rising, people view their home as investments and are willing to spend more on them.

She said she does not see the election results has having a material impact on Home Depot's forecasts.

When asked about growth, Tomé said that the total addressable market in the U.S. is $550 billion and Home Depot only has a 20% share, leaving lots of room for growth. She was also bullish on the company's business in Mexico.

Cramer and Tomé also discussed Home Depot's commitment to shareholders: The company has purchased over $65 billion worth of its own shares, and is committed to helping the communities it serves, with rapid responses to hurricanes and other natural disasters.

A Special Invitation

It's not how you voted, it's how you invest. So how can investors win in the wake of this historical election? If you're planning to be in New York on Tuesday, Dec. 6, you are invited to join senior editors from TheStreet and our special guest experts for a cocktail party and lively conversation about the outlook for the U.S. financial markets. Which companies and sectors are poised to profit? What shocks and opportunities await investors in the new year? Listen to and meet our panelists: Lew Altfest, CEO of Altfest Personal Wealth Management; Barry Ritholtz, founder of Ritholtz Wealth Management; and Larry Siegel, director of research at the CFA Institute Research Foundation, with moderator Robert Powell. This evening event is free and will be held at The Harvard Club of New York. Reservations are required. For more information or to RSVP, please email events@thestreet.com
 
Are you in it for the long term? So are Jim Cramer and Jack Mohr. They've just updated their core holdings for Action Alerts PLUS. See what they're telling their members about Comcast ( CMCSA) , Starbucks SBUX , Walgreens ( WBA) and more with a free trial membership to this investment club.

Corbus Pharmaceuticals (CRBP)  : Cramer spoke with Dr. Yuval Cohen, CEO of Corbus Pharmaceuticals (CRBP) , the biotech with a stock that's up a whopping 380% so far this year.

Cohen commented on the recent Phase II results for Resunab, his company's drug to treat cystic fibrosis and systemic sclerosis. He said that while Phase II studies are small and the first to be conducted in actual patients, the signal received from Resunab results was stronger than expected.

When asked about the need to raise additional money to continue with their trials, Cohen noted that Corbus is fortunate to have sponsors for their trials, including a $5 million grant from the Cystic Fibrosis Foundation to study Resunab.

Cramer said while Corbus remains speculative, the company's outlook continues to appear promising.

A healthy move: Cramer and Jack Mohr are adding shares of Allergan (AGN) . Find out why with a free trial membership to Action Alerts PLUS.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had positions in CMCSA, WBA and AGN.

More from Stocks

What You Need to Know About Facebook and Europe's New Privacy Rules

What You Need to Know About Facebook and Europe's New Privacy Rules

8 Bold Moves General Motors Could Make to Rev Up Its Battered Stock Price

8 Bold Moves General Motors Could Make to Rev Up Its Battered Stock Price

Is Your Investment Portfolio Prepared for Trade Wars, Inflation and More Trump?

Is Your Investment Portfolio Prepared for Trade Wars, Inflation and More Trump?

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric